Novo Nordisk/Aradigm Inhaled Insulin Study For Type 1 Diabetes Raises Efficacy Concern

Clinical focus could shift solely to type 2 diabetes. Interim analysis shows unexpected delay in post-meal glucose suppression, but Novo and Aradigm say positive safety results make data “very usable in our regulatory filing.”